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Abstract: The true benefits of robotic surgery are controversial, and
whether robotic total mesorectal excision (R-TME) can be justified as a
standard treatment for rectal cancer patients needs to be clarified. This
case-matched study aimed to compare the postoperative complications
and short- and long-term outcomes of R-TME and laparoscopic TME
(L-TME) for rectal cancer.
Among 1029 patients, we identified 278 rectal cancer patients who
underwent R-TME. Propensity score matching was used to match this
group with 278 patients who underwent L-TME.
The mean follow-up period was similar between both groups (L-
TME vs R-TME: 52.5 17.1 vs 51.0 13.1 months, P¼ 0.253), as
were patient characteristics. The operation time was significantly longer
in the R-TME group than in the L-TME group (361.6 91.9 vs
272.4 83.8min; P< 0.001), whereas the conversion rate, length of
hospital stay, and recovery of pain and bowel motility were similar
between both groups. The rates of circumferential resection margin
involvement and early complications were similar between both groups
(L-TME vs R-TME: 4.7% vs 5.0%, P¼ 1.000; and 23.7% vs 25.9%,
P¼ 0.624, respectively), as were the 5-year overall survival, disease-
free survival, and local recurrence rates (93.1% vs 92.2%, P¼ 0.422;
79.6% vs 81.8%, P¼ 0.538; 3.9% vs 5.9%, P¼ 0.313, respectively).
The oncologic quality, short- and long-term outcomes, and post-
operative morbidity in the R-TME group were comparable with those in
the L-TME group.
(Medicine 94(11):e522)
Abbreviations: BMI = body mass index, CRM = circumferential
resection margin, CUSUM = cumulative sum, MIS = minimally
invasive surgery, TME = total mesorectal excision, TNM = tumor
nodes metastasis.
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invasive surgery (MIS). Evolution of the surgical techniques
and the introduction of more advanced instruments for color-
ectal surgery have resulted in several advantages such as better
cosmesis, quicker recovery, less postoperative pain, and a
decreased hospital stay.1–5 Several recent randomized clinical
trials have moreover demonstrated that laparoscopic total
mesorectal excision (TME) shows superiority in terms of the
short-term outcomes compared with open TME.6,7 Further-
more, a number of large-scale clinical trials have demonstrated
similar outcomes between open surgery and laparoscopic
surgery in the treatment of colorectal cancer in terms of their
oncologic adequacy and long-term oncologic outcomes.8–11
Robotic systems combined with this trend have been
developed as one of the treatment options for rectal cancer
patients; however, to date, TME is still regarded as a technically
demanding and oncologically critical procedure, especially in
patients with challenging circumstances such as a narrow pelvis,
lower rectal tumor, and anatomical complexity.2,12 Robotic
surgery for rectal cancer theoretically has several advantages
compared with laparoscopic surgery.13,14 Recently, our institu-
tion demonstrated that robot-assisted tumor-specific mesorectal
excision for rectal cancer was technically feasible and a safe
surgical option in terms of the long-term oncologic out-
comes.15,16 However, there are still limited reports regarding
the true benefits of robotic TME (R-TME). Furthermore, there
is currently no case-matched study comparing the long-term
oncologic outcomes between R-TME and laparoscopic TME
(L-TME). Therefore, to clarify the true benefits of robotic
surgery in the treatment of rectal cancer, this case-matched
study aimed to evaluate the short- and long-term outcomes
between totally robotic and L-TME for rectal cancer.
METHODS
Patient Selection
This study is a case-matched retrospective study. Between
January 2007 and June 2011, a total of 1029 patients who
underwent laparoscopic or robotic surgery for the treatment of
colorectal disease were identified from the Yonsei Colorectal
Cancer Electronic Database that covers institutional data.
Among these 1029 patients, 127 patients who underwent hybrid
R-TME and 23 patients with incomplete data were initially
excluded. Other exclusion criteria included: stage IV disease,
familial adenomatous polyposis or hereditary non-polyposis
colorectal cancer, benign disease, R1 or R2 resection, tumor
located >15.0 cm from the anal verge, previous or concurrent
malignant disease, abdominoperineal resection, and Hartmanidentified 278 patients who underwent
tal adenocarcinomas. Propensity score
match this group in a 1:1 ratio with 278
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patients who underwent conventional L-TME. Covariates used
in the logistic regression model for calculating the propensity
score were age, sex, body mass index (BMI), tumor location,
operation method (low anterior resection or coloanal anasto-
mosis), neoadjuvant treatment, adjuvant treatment, and patho-
logic TNM stage (Figure 1). All patients were assessed
preoperatively by using rectal magnetic resonance imaging
(MRI), transrectal ultrasonography (TRUS), colonoscopy, and
chest and abdominal computed tomography (CT). This study
was approved by the Institutional Review Board of Severance
Hospital.
Surgeon Validation
All surgeries were performed by 5 surgeons of the division
of colorectal surgery at Severance Hospital, Yonsei University
Health System. All surgeons who performed R-TME had
completed the MIS training program at the same institution.
Most of the robotic cases (97.1%) were performed by 3 sur-
geons. Among them, 2 surgeons were primarily trained in
laparoscopic colorectal surgery. One surgeon underwent laparo-
scopic and robotic colorectal surgery training around the same
time. To assess the surgeons’ proficiency, the cumulative sum
(CUSUM) method was used to quantitatively evaluate the
learning curve.17
Surgical Method
All patients underwent surgical treatment by either L-TME
or R-TME. At our institution, we used the robotic da Vinci
Surgical System (Intuitive Surgical, Sunnyvale, CA, USA) to
perform R-TME via 2 different techniques: a hybrid robotic
technique or totally robotic technique. In the present study, only
patients who underwent totally robotic TME were included.
Totally R-TME for rectal cancer surgery consists of 2 phases.
Cho et alThe first phase is the colonic phase, which comprises inferior
mesenteric vessel ligation and left colon and splenic flexure
mobilization. The second phase is the pelvic phase, which
Total = 1029
Laparoscopy 587
Robotic 442
Between Jan 2007 and Dec 2011
Total = 879
Laparoscopy 572
Totally robotic 307
Laparoscopy 499 Totally robo
Laparoscopy 278 Totally robo
FIGURE 1. Flowchart of patient selection.
2 | www.md-journal.comconstitutes pelvic dissection using the TME principles. The
detailed procedures for both L-TME and R-TME have been
previously described.18,19
Neoadjuvant and Adjuvant Treatment
Neoadjuvant chemotherapy was performed on patients
who had a tumor on the rectal wall or those with invasion to
the adjacent pelvic organs. These patients with locally advanced
tumors were diagnosed with adenocarcinoma via endoscopic
biopsy (stage T3 or T4) and had clinically enlarged regional
lymph nodes identified by TRUS and rectal MRI. For neoadju-
vant chemoradiation therapy, we used a standard long-course
regimen of 5-fluorouracil-based chemotherapy and a total dose
of 50.4 Gy of external beam radiation. Adjuvant chemotherapy
was administered based on the pathology report and by using the
National Comprehensive Cancer Network guidelines.
Patient Follow-Up
All patients were followed-up at 3-month intervals for the
first 2 years. The follow-up intervals were decreased to every 6
months during the third through the fifth year, and annually
thereafter. At each follow-up, the patients underwent physical
examinations, blood tests with measurement of serum carci-
noembryonic antigen levels, and chest radiography. Abdomi-
nopelvic CT and whole-body bone scans were performed
annually. TRUS, colonoscopy, chest CT, pelvic MRI, and
positron emission tomography with fludeoxyglucose were per-
formed at the physician’s discretion.
Surgical Complications
Complications were defined as any deviations from the
Medicine  Volume 94, Number 11, March 2015general postoperative course. Early and late complications were
defined as postoperative complications that occurred within and
after 30 days, respectively. We used a modified classification
tic 278
Exclusion criteria 1
Exclusion criteria 2
1:1 Propensity score
matching
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2. Tumor location
3. Operation method
4. Neoadjuvant CRT
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Shsystem that included 5 grades of severity to stratify surgical
complications.20
Recurrence Classification
The medical records of all patients were reviewed to gather
information about tumor recurrence. Recurrence patterns were
classified into 2 groups: local and systemic recurrence. Local
recurrence was defined as any clinical or histological evidence
of tumor re-growth near the primary site after the initial
operation, and absence of distant metastasis. Systemic recur-
rence was defined as local recurrence with any distant metas-
tasis confirmed by imaging studies or histological biopsy.
Statistical Analysis
Propensity matching was conducted using R project for
Statistical Computing, Version 2.12.0 (R Development Core
Team, Vienna, Austria) along with the SPSS R Essentials plug-
in. Logistic regression was used to estimate the propensity
scores for each group. Eight covariates were included in the
logistic regression model for calculating the propensity score. A
simple nearest neighbor matching algorithm was conducted to
achieve the best covariate balance after matching. Units outside
the area of common support were disregarded to further
improve the balance of the covariates. A Jitter plot was used
for assessing the overall propensity score distribution between
the groups.
Categorical variables were analyzed by using the x2 test,
and continuous variables were analyzed by using Student t test.
The Kaplan–Meier method was used to calculate the 5-year
local recurrence rate (LRR) and systemic recurrence rate (SRR),
as well as the overall survival (OS), disease-specific survival
(DSS), and disease-free survival (DFS) rates after surgery. OS
was defined as the time from surgery to death from any cause.
Medicine  Volume 94, Number 11, March 2015DSS was defined as the time from surgery to death related to
cancer. DFS was defined as the time from surgery to any
recurrence. All postoperative complications were analyzed
Distribution of propensity scores
Unmatched treatment units
Matched treatment units
Matched control units
Unmatched control units
Propensity score
0.2 0.4 0.6 0.8
FIGURE 2. A Jitter plot of propensity score and histogram of standa
distribution between treatment (R-TME) and control (L-TME) groups.
total mesorectal excision.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.using binary logistic regression. SPSS software version 20.0
for Windows (SPSS Inc, Chicago, IL, USA) was used for all
analyses. All P values were 2-sided, and P< 0.05 was con-
sidered statistically significant.
RESULTS
A total of 556 patients (278 matched pairs) were included
in this study. The mean follow-up period was 51.8 15.3
months (L-TME vs R-TME: 52.5 17.1 vs 51.0 13.1 months,
P¼ 0.253). Figure 2 shows the distribution of the propensity
scores of the matched treatment (R-TME) and control (L-
TME) groups.
Patient Characteristics
The demographic characteristics of the patients are pre-
sented in Table 1. There were no significant differences
between the L-TME and R-TME groups in the adjusted analysis
using one-to-one propensity score matching, and no relevant
differences were found between the 2 groups in terms of age,
sex, BMI, American Society of Anesthesiologists score, tumor
location, operation method, pathologic TNM stage, history of
previous abdominal surgery, mean preoperative carcinoem-
bryonic antigen levels, and neoadjuvant or adjuvant treatment.
Comparison of Postoperative Surgical Details
and Short-term Outcomes
Comparisons of the postoperative surgical details and
recovery in patients who underwent L-TME versus R-TME
are summarized in Table 2. No relevant differences were found
between the groups in terms of the operation method, rate of
combined resection, conversion rate, and estimated blood loss.
The most common resection type in both groups was low
ort and Long-term Outcomes of R-TME Vs L-TME for Rectal Canceranterior resection (L-TME vs R-TME: 84.5% vs 80.9%), and
the ratio of the resection type did not significantly differ
between the 2 groups (P¼ 0.313). Two (0.7%) patients in
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TABLE 1. Demographic Characteristics by Using Propensity Score Matching
After Case Matching Before Case Matching
L-TME (n¼ 278) R-TME (n¼ 278) P Value L-TME (n¼ 499) R-TME (n¼ 278) P Value
Age, y, mean 58.3 10.4 57.4 11.6 0.144 62.4 10.6 57.4 11.6 <0.001
Sex 0.929 0.352
Male 184 (66.2%) 182 (65.5%) 309 (61.9%) 182 (65.5%)
Female 94 (33.8%) 96 (34.5%) 190 (38.1%) 96 (34.5%)
BMI, kg/m2 23.7 3.3 23.5 2.9 0.522 23.5 3.1 23.5 2.9
ASA 0.773 <0.001
I-II 250 (89.9%) 253 (91.0%) 401 (80.4%) 253 (91.0%)
III-IV 28 (10.1%) 25 (9.0%) 98 (19.6%) 25 (9.0%)
Distance from AV, mean 8.0 2.8 7.7 2.8 0.227 9.1 3.1 7.7 2.8 <0.001
Tumor level, n (%) 0.184 <0.001
Lower tumor 51 (18.3%) 69 (24.8%) 60 (12.0%) 69 (24.8%)
Middle tumor 187 (67.3%) 172 (61.9%) 303 (60.7%) 172 (61.9%)
Upper tumor 40 (14.4%) 37 (13.3%) 136 (27.3%) 37 (13.3%)
Neoadjuvant treatment 0.311 <0.001
No 199 (71.6%) 187 (67.3%) 393 (78.8%) 187 (67.3%)
Yes 79 (28.4%) 91 (32.7%) 106 (21.2%) 91 (32.7%)
Adjuvant treatment 1.000 0.072
No 97 (34.9%) 96 (34.5%) 205 (41.1%) 96 (34.5%)
Yes 181 (65.1%) 182 (65.5%) 294 (58.9%) 182 (65.5%)
Previous abdominal surgery 0.135 0.134
No 216 (77.7%) 231 (83.1%) 391 (78.4%) 231 (83.1%)
Yes 62 (22.3%) 47 (16.9%) 108 (21.6%) 47 (16.9%)
Preoperative CEA, mean 5.76 13.6 5.38 14.0 0.747 5.37 11.7 5.38 14.0 0.989
I¼
isio
Cho et al Medicine  Volume 94, Number 11, March 2015the L-TME group initially had to undergo open surgery because
ASA¼American Society of Anesthesiologists, AV¼ anal verge, BM
scopic total mesorectal excision, R-TME¼ robotic total mesorectal excof severe tumor adhesion and intractable major vessel bleeding.
In the R-TME group, 1 (0.4%) patient was required to undergo
laparoscopic surgery because of bowel perforation. The total
TABLE 2. Postoperative Surgical Details and Short-term Outcom
L-TME (n¼ 278)
Operation method, n (%)
LAR 235 (84.5%)
CAA 43 (15.5%)
Ileostomy, n (%) 85 (30.6%)
Combined resection, n (%)
No 264 (95.0%)
Yes 14 (5.0%)
Conversion rate, n (%) 2 (0.7%)
Total operation time, min 272.4 83.8
Estimated blood loss, mL 147.0 295.3
Length of hospital stay, d 10.7 6.6
Time to first flatus, d 2.9 1.3
Time to first liquid diet, d 3.7 1.9
Time to first soft diet, d 4.7 2.5
VAS score, mean
POD 0 4.4 1.4
POD 1 3.6 1.1
POD 2 3.5 1.3
CAA¼ coloanal anastomosis, LAR¼ low anterior resection, L-TME¼ la
excision, POD¼ postoperative of day, VAS¼ visual analog scale.
4 | www.md-journal.comoperation time was significantly longer in the R-TME group
body mass index, CEA¼ carinoembryonic antigen, L-TME¼ laparo-
n, SD¼ standard deviation.(361.6 91.9 vs 272.4 83.8min; P< 0.001). Combined
resection in the L-TME group was performed for 14 (5.0%)
patients, of whom 7, 2, 1, 1, and 1 patients underwent
es
R-TME (n¼ 278) P Value
0.313
225 (80.9%)
53 (19.1%)
108 (38.8%) 0.050
0.100
266 (95.7%)
12(4.3%)
1 (0.4%) 1.000
361.6 91.9 <0.001
179.0 236.5 0.159
10.4 5.6 0.564
2.8 1.4 0.411
3.5 2.2 0.309
4.5 2.9 0.382
4.4 1.5 0.816
3.6 1.2 0.698
3.5 1.2 0.973
paroscopic total mesorectal excision, R-TME¼ robotic total mesorectal
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
Shcholecystectomy due to gallstones, incidental appendectomy,
hysterectomy due to uterine myoma, partial cystectomy due to
bladder wall invasion, and extensive en bloc resections due to
invasion into the small bowel wall, respectively. The remaining
2 patients underwent benign colonic mass excisions and biopsy
of liver nodules. Twelve (4.3%) patients in the R-TME group
underwent combined resection. Four patients underwent hys-
terectomy with bilateral oophorectomy owing to tumor invasion
into the uterus. The other 8 patients underwent benign mass
excision, including oophorectomy (n¼ 2), cholecystectomy
(n¼ 3), inguinal hernioplasty (n¼ 1), wedge resection of the
stomach due to gastrointestinal stromal tumor (n¼ 1), and
excision of a urachal cyst (n¼ 1).
Postoperative Pathologic Outcomes
The pathologic stages did not significantly differ between
the groups. The mean number of retrieved lymph nodes (L-
TME vs R-TME: 16.2 8.1 nodes vs 15.0 8.1 nodes,
P¼ 0.069) and the proportion of patients with <12 nodes
harvested (30.2% vs 37.8%, P¼ 0.073) were not significantly
different between the groups. Moreover, there was no difference
in the proportion of patients with a positive circumferential
resection margin (CRM) (L-TME vs R-TME: 4.7% vs 5.0%;
Medicine  Volume 94, Number 11, March 2015P¼ 1.000). In addition, both the mean length of the proximal
and distal resection margin was not significantly different
between the groups. Other pathologic outcomes, including
TABLE 3. Postoperative Pathologic Outcomes
L-TME (n¼ 278)
Tumor size, cm 3.1 2.1
Length of resection margin, cm
Proximal 11.2 6.1
Distal 2.2 1.4
Resection margin involvement
Distal 3 (1.1%)
CRM (1.0mm) 13 (4.7%)
LVI, n (%) 43 (15.5%)
Total No. of harvested LN 16.2 8.1
No. of case with <12 LN 84 (30.2%)
p(or yp) T
T0,Tis 42 (15.1%)
T1 27 (9.7%)
T2 71 (25.6%)
T3 129 (46.4%)
T4 9 (3.2%)
p(or yp) N
N0 184 (66.2%)
N1 74 (26.6%)
N2 20 (7.2%)
p(or yp) TNM stage (AJCC 7th)
Stage 0, pCR 37 (13.3%)
Stage I 76 (27.3%)
Stage II 71 (25.5%)
Stage III 94 (33.8%)
Histology
G1/G2 270 (97.1%)
G3 8 (2.9%)
AJCC¼American Joint Committee on Cancer, CRM¼ circumferential re
G3¼ poorly differentiated, L-TME¼ laparoscopic total mesorectal excisio
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.tumor size, rate of lymphovascular invasion, grade of tumor
differentiation, and pathologic T and N stage, were not signifi-
cantly different between both groups (Table 3).
Postoperative Complications
Both the overall early and late complications showed no
significant differences between the groups. Early postoperative
complications (within 30 days) occurred in 66 of 278 patients
(23.7%) in the L-TME group and in 72 of 278 (25.9%) patients
in the R-TME group. Anastomotic leakage was the most
common type of early complication in both groups, and the
rate of anastomotic leakage did not differ between the groups
(L-TME vs R-TME: 10.8% vs 10.4%, P¼ 1.000). The second
most common early complication in both groups was intestinal
obstruction (L-TME vs R-TME: 3.2% vs 5.8%). Late compli-
cations (>30 days) occurred in 56 of 278 patients (20.1%) in the
L-TME group and in 66 of 278 (23.7%) patients in the R-TME
group (Table 4). The most common late complication in both
groups was intestinal obstruction (L-TME vs R-TME: 5.0% vs
5.4%). In terms of functional outcomes, the rate of sexual
dysfunction did not differ between the groups (L-TME vs R-
TME: 2.2% vs 2.5%). However, the rate of voiding dysfunction
was significantly higher in the L-TME group (4.3% vs 0.7%).
ort and Long-term Outcomes of R-TME Vs L-TME for Rectal CancerAccording to the Clavien-Dindo classification, 32 patients
(11.5%) in the L-TME group were found to have Grade I–II
complications, whereas 38 patients (13.7%) in the R-TME
R-TME (n¼ 278) P Value
2.9 1.9 0.299
10.8 6.0 0.536
2.0 1.4 0.161
1 (0.4%) 0.624
14 (5.0%) 1.000
45 (16.2%) 0.908
15.0 8.1 0.069
105 (37.8%) 0.073
0.722
48 (17.3%)
29 (10.4%)
75 (27.0%)
121 (43.5%)
5 (1.8%)
0.750
194 (69.8%)
62 (22.3%)
22 (7.9%)
0.725
44 (15.8%)
78 (28.1%)
73 (26.3%)
83 (29.9%)
1.000
271 (97.5%)
7 (2.5%)
section margin; G1/G2¼moderately differentiated/ well differentiated,
n, LN¼ lymph node, R-TME¼ robotic total mesorectal excision.
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TABLE 4. Postoperative Early and Late Complications
Early Complications Within 30 Days Late Complications After 30 Days
L-TME
(n¼ 278)
R-TME
(n¼ 278)
P
Value
L-TME
(n¼ 278)
R-TME
(n¼ 278)
P
Value
Overall 66 (23.7%) 72 (25.9%) 0.624 Overall 56 (20.1%) 66 (23.7%) 0.356
Upper rectum 7/40 (2.5%) 6/37 (2.2%) 1.000 Upper rectum 4/40 (%) 4/37 1.000
Middle rectum 50/187 (17.9%) 43/172 (15.5%) 0.719 Middle rectum 39/187 (%) 34/172 0.896
Lower rectum 9/51 (3.3%) 23/69 (8.2%) 0.062 Lower rectum 13/51 (%) 28/69 0.119
Type of complications Surgery-related complications
Anastomotic leakage 30 (10.8%) 29 (10.4%) 1.000 Intestinal obstruction 14 (5.0%) 15 (5.4%)
Intestinal obstruction 9 (3.2%) 16 (5.8%) Delayed leakage 1 (0.4%) 3 (1.1%)
Urinary complication 11 (4.0%) 5 (1.8%) Rectovaginal fistula 4 (1.4%) 4 (1.4%)
Wound infection 1 (0.4%) 2 (0.7%) Sexual dysfunction 6 (2.2%) 7 (2.5%) 1.000
Bleeding 1 (0.4%) 3 (1.1%) Voiding dysfunction

12 (4.3%) 2 (0.7%) 0.012
Chyle ascites 3 (1.1%) 2 (0.7%) ntractable fecal incontinence 3 (1.1%) 6 (2.2%)
Bowel ischemia 1 (0.4%) 2 (0.7%) Anastomotic stricture 3 (1.1%) 10 (3.6%)
Rectovaginal fistula 3 (1.1%) 2 (0.7%) Wound complication 1 (0.4%) 2 (0.7%)
Intraabdominal abscess 4 (1.4%) 3 (1.1%) Incisional hernia 4 (1.4%) 1 (0.4%)
Bowel injury 0 (0.0%) 1 (0.4%) Ischemic colitis 1 (0.4%) 3 (1.1%)
C-P complication 2 (0.7%) 2 (0.7%) Perianal fistula 0 (0.0%) 1 (0.4%)
Others 1 (0.4%) 5 (1.8%) Pelvic abscess 0 (0.0%) 1 (0.4%)
C-D Classification Rectal prolapse 0 (0.0%) 1 (0.4%)
Grade I-II 32 (11.5%) 38 (13.7%) 0.523 Others
Grade III-IV 34 (12.2%) 34 (12.2%) 1.000 Chemotherapy-related 6 (2.2%) 10 (3.6%)
Postoperative mortality 1 (0.4%) 0 (0.0%) 1.000 Pneumonia 1 (0.4%) 0 (0.0%)
C-D¼Clavien-Dindo, C-P¼ cardiopulmonary, L-TME¼ laparoscopic total mesorectal excision, R-TME¼ robotic total mesorectal excision,
12 m
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Cho et al Medicine  Volume 94, Number 11, March 2015group had Grade I–II complications. However, 34 patients
(12.2%) in the L-TME group and 34 patients (12.2%) in the
R-TME group were reported to have Grade III–IV compli-
cations. One patient (0.4%) in the L-TME group died of cardiac
arrest during the immediate postoperative period (Table 4).
Comparison of Tumor Recurrence Pattern and
Long-term Oncologic Outcomes
There was no significant difference in the overall tumor
recurrence between the groups (P¼ 0.660). Tumor recurrence,
including both local and systemic recurrences, occurred in 53
patients (19.1%) in the L-TME group and in 49 patients (17.3%)
in the R-TME group during the study period. Among all patients
who underwent L-TME, 6 patients (2.2%) had local recurrence
without systemic recurrence, and 44 patients (15.8%) had
systemic recurrence without local recurrence. In the R-TME
group, 5 patients (1.8%) had local recurrence without systemic
recurrence and 34 patients (12.2%) had systemic recurrence.
Local and systemic recurrence was observed in 3 patients
(1.1%) in the L-TME group and 9 patients (3.3%) in the R-
TME group. The overall 5-year LRR (Figure 3) and SRR were
3.9% and 18.0% in the L-TME group and 5.9% and 16.3% in R-
TME group, respectively. In the multivariate analysis of risk
factors for local recurrence, postoperative complications higher
than grade III (P¼ 0.005;HR¼ 3.674; 95%CI 1.485–9.090) and
CRM involvement (P¼ 0.002; HR¼ 5.653; 95% CI 1.877–
TME¼ total mesorectal excision.
Patients who underwent follow-up urodynamic study at 1, 3, 6, and
filled out questionnaires (international prostate symptom score [IPSS])17.028)were found tobe independentprognostic factors,whereas
tumor size >3.0 cm (P¼ 0.049; HR¼ 1.600; 95% CI 1.001–
2.556), stage III disease (P< 0.001; HR¼ 3.232; 95%CI 1.964–
6 | www.md-journal.com5.318), and CRM involvement (P¼ 0.034; HR¼ 2.090; 95% CI
1.059–4.127) were found to be independent prognostic factors
for systemic recurrence (Table 5).
In terms of the long-term oncologic outcomes, 5-year OS
(L-TME vs R-TME: 93.1% vs 92.2%; P¼ 0.422), 5-year DSS
(L-TME vs R-TME: 95.5% vs 93.6%; P¼ 0.120) and 5-year
DFS (L-TME vs R-TME: 79.6% vs 81.8%; P¼ 0.538) were
found to be similar between the groups (Figure 3). Additionally,
when the patients were analyzed according to the disease stage,
there were no significant differences between the groups. The
5-year OS rates for L-TME versus R-TME for stage 0, I, II, and
III disease were 100.0% vs 90.9% (P¼ 0.062), 98.7% versus
95.4% (P¼ 0.345), 89.0% versus 91.6% (P¼ 0.409), and
89.0% versus 91.2% (P¼ 0.577), respectively. The 5-year
DSS rates for L-TME versus R-TME for stage 0, I, II, and
III disease were 100.0% versus 93.0% (P¼ 0.104), 100.0%
versus 97.9% (P¼ 0.350), 95.8% versus 92.9% (P¼ 0.594), and
90.0% versu1s 91.2% (P¼ 0.417), respectively. The 5-year
DFS rates for L-TME versus R-TME for stage 0, I, II, and
III disease were 90.5% versus 95.4% (P¼ 0.504), 88.3% versus
89.5% (P¼ 0.947), 86.2% versus 81.2% (P¼ 0.437), and
63.2% versus 68.2% (P¼ 0.410), respectively. In the multi-
variate analysis, prognostic factors impacting the 5-year OS
were stage III disease (P¼ 0.048; HR¼ 1.919; 95% CI 1.004–
3.666) and high grade of differentiation (P¼ 0.004;
HR¼ 3.907; 95% CI 1.196–12.767) (Table 5).
onths after surgery due to persistent urinary dysfunction or those who
the same reason were categorized into prolonged voiding dysfunction.DISCUSSION
The aim of this study was to compare the short- and long-
term outcomes in an attempt to investigate the impact of R-TME
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Medicine  Volume 94, Number 11, March 2015 Short and Long-term Outcomes of R-TME Vs L-TME for Rectal Canceron rectal cancer. This case-matched study, which included
>500 patients with long-term follow-up data, revealed no
significant differences in the short-term outcomes, rate of
postoperative complications, oncologic quality, tumor recur-
rence, or the 5-year OS, and the DFS rates. However, our
study showed that R-TME was significantly associated with
a much lower incidence of late voiding dysfunction than
L-TME (0.7% vs 4.3%, P¼ 0.012). Although the introduction
of TME has resulted in improved genitourinary functional
preservation, most colorectal surgeons are still faced with
challenging conditions such as injuries to the hypogastric
nerves and/or the sacral splanchnic nerve during pelvic dis-
section.21,22 Recently, Kim et al23 showed that R-TME was
significantly associated with earlier recovery in voiding and
sexual function compared with L-TME. Similarly, Luca F
et al24 demonstrated that R-TME allowed for better preser-
vation of urinary and sexual functions compared with L-TME,
and concluded that this may be attributed to superior move-
ment of the wristed instruments, and to the precise pelvic
dissection with better dexterity under stable magnified view.
Theoretically, the use of a robotic system can decrease the
risk of collateral injury to the pelvic autonomic nerves.
However, there are currently only limited studies evaluating
the impact of robotic technology on urogenital complications
after TME. Thus, whether these theoretical advantages of
R-TME translate into significant favorable urogenital func-
tion still remains to be determined. Randomized clinical trials
such as the COLRAR trial (NCT01423214) and ROLARR
FIGURE 3. (A) 5-year overall survival, (B) disease-specific, (C) diseas
robotic TME (all P values were not significant). TME¼ total mesotrial (NCT01196000) are currently ongoing to clarify this
issue, and more objective data may be obtained from these
clinical trials in the future.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Owing to the many advantages of MIS, surgeons pre-
viously performing rectal surgery using the open technique
have begun to show interest in the feasibility of transitioning
into the MIS technique. On the basis of this trend, many
colorectal surgeons have evaluated the true benefits of robotic
technology, which overcomes the technical limitations of
L-TME. Kang et al25 showed that R-TME in the treatment
of mid or low rectal cancer was associated with decreased
analgesia use, less postoperative pain, and a shorter hospital
stay. Recently, Park et al furthermore reported that the rate of
conversion was significantly lower for R-TME than L-TME
(0.0% vs 7.1%, P¼ 0.003).16 Similarly, the short-term out-
comes from 2 meta-analyses revealed that R-TME was associ-
ated with a significantly lower conversion rate and equivalent
oncologic adequacy compared with L-TME.26,27 However,
there were several possible confounding factors, especially
regarding the conversion rate. Moreover, Kang et al showed
similar conversion rates between R-TME and L-TME (0.6% vs
1.8%, P¼ 0.623), and similarly, the rates of conversion in this
study did not significantly differ between the groups (R-TME vs
L-TME: 0.4% vs 0.7%, P¼ 1.000). This result may be
explained by several factors: first, the designs of most of the
previous studies were heterogeneous. In the present study,
propensity score matching with 8 clinical factors that may
potentially affect the surgical outcomes was used to reduce
patient selection biases. Although there are inevitable hidden
selection biases from unmatched variables, propensity score
matching is a useful method for reducing selection bias between
ee survival, and (D) local recurrence rate between laparoscopic and
al excision.groups, and we believe that our case-matched study design may
have potentially contributed to the similar conversion rates
among the groups. Second, in most of the previous reports,
www.md-journal.com | 7
TABLE 5. Univariate and Multivariate Analysis of Affecting Factors for Tumor Recurrence and Overall Survival
Local Recurrence Systemic Recurrence Overall Survival
Variables Univariate
Multivariate
(95% CI) P Univariate
Multivariate
(95% CI) P Univariate
Multivariate
(95% CI) P
Procedure laparoscopy
vs robotic
0.148 0.860 0.947
Resection type LAR
vs CAA
0.600 0.749 0.472
Sex (Male) 0.075 0.115 0.520
Age (60) 0.600 0.056 0.068
BMI (25 kg/m2) 0.074 0.302 0.824
ASA (III) 0.214 0.607 0.670
Smoking 0.164 0.913 0.559
Alcohol 0.050 0.586 0.271
Tumor location AV
<5.0 cm
0.580 0.500 0.504
CCRT 0.450 0.593 0.892
Ileostomy 0.116 0.791 0.646
Combined resection 0.812 0.055 0.201
Operative time
240min
0.062 0.271 0.973
Blood loss 500mL 0.746 0.845 0.395
PAS 0.470 0.894 0.183
Complications
Grade I-II 0.190 0.939 0.680
Grade III-IV 0.004 3.674
(1.485–9.090)
0.005 0.327 0.413
Tumor size 3.0 cm 0.440 0.018 1.600
(1.001–2.556)
0.049 0.121
TNM stage III 0.091 <0.001 3.232
(1.964–5.318)
<0.001 0.048 1.919
(1.004–3.666)
0.048
LVI 0.073 <0.001 1.512
(0.919–2.489)
0.104 0.148
CRM involvement 0.001 5.653
(1.877–17.028)
0.002 0.005 2.090
(1.059–4.127)
0.034 0.743
Histology G1/2 vs G3 0.401 0.004 4.546
(1.939–10.657)
<0.001 0.017 3.907
(1.196–12.767)
0.004
LN 12 0.613 0.238 0.283
ASA¼American Society of Anesthesiologists, AV¼ anal verge, BMI¼ body mass index, CAA¼ coloanal anastomosis, CCRT¼ concurrent
ntia
lym
Cho et al Medicine  Volume 94, Number 11, March 2015the proficiency of TME by a single or multiple surgeons was not
assessed using objective parameters. Although CUSUM score
graphs was not provided in the text, we analyzed a learning
curve of R-TME to minimize confounding surgeon-related
factors in this study. Our results of the CUSUM analysis
indicated that no definite peak point of the learning curve for
R-TMEwas found in 2 skilled surgeons with previous extensive
laparoscopic experience, and this may, at least partly, explain
the equivalent conversion rate between the groups. However,
although CUSUM plots are useful for evaluating the degree of a
surgeon’s proficiency, the current study did not offer a full
explanation for the low rate of conversion in the R-TME group.
Therefore, further randomized clinical trials are required to
elucidate the technical benefits of robotic surgery by using
chemoradiation treatment, CI¼ confidence interval, CRM¼ circumfere
tiated, G3¼ poorly differentiated, LAR¼ low anterior resection, LN¼
surgery.conversion rate as an endpoint.
Moreover, questions still remain whether R-TME have any
influence on the oncologic outcomes and postoperativemorbidity
8 | www.md-journal.comin rectal cancer patients, as compared with L-TME. Although the
currently available data are limited, recent studies have reported
at least equivalency between L-TME and R-TME in terms of
critical perioperative outcomes such as postoperative compli-
cations, CRM involvement rate, and lymph node yield.13,16,25,28
Consistent with these previous studies, our study showed equiv-
alent outcomes between L-TME and R-TME, including regard-
ing the quality of oncologic resection, such as CRM involvement
(L-TME vs R-TME: 4.7% vs 5.0%, P¼ 1.000), lymph node
harvest (L-TMEvsR-TME: 16.2 8.1 vs 15.0 8.1,P¼ 0.069),
and rate of postoperative complications. CRM, which has been
reported to be associated with local recurrence, can be used as an
indicator of the quality of TME.29,30 Accordingly, in this study,
CRM involvement was found to be significantly associated with
l resection margin, G1/G2¼moderately differentiated/ well differen-
ph node, LVI¼ lymphovascular invasion, PAS¼ previous abdominaltumor recurrence in both techniques.
In terms of the long-term oncologic aspects, previous
comparative studies have reported similar 3-year oncologic
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
Shoutcomes between R-TME and L-TME.28,31,32 Recently, Baik
et al reported that there was no significant difference in terms of
the 5-year LRR and OS and DFS rates (2.3% vs 1.2%,
P¼ 0.649; 92.8% v 93.5%, P¼ 0.829; 81.9% vs 78.7%,
P¼ 0.547, respectively) between hybrid R-TME and L-
TME.16 Similarly, the present study also demonstrated similar
long-term oncologic outcomes between R-TME and L-TME in
terms of the 5-year LRR (5.9% vs 3.9%, P¼ 0.313) and OS
(92.2% vs 93.1%, P¼ 0.422) and DFS (81.8% vs 79.6%,
P¼ 0538) rates. Based on the data presented in our study,
we conclude that both R-TME and L-TME provided acceptable
long-term oncologic outcomes in rectal surgery. However,
similar to in the previous reports, R-TME did not show any
superior oncologic benefits over L-TME in this study.
In the present study, major complications occurred in 68
(12.2%) patients. Among these patients, 59 (86.7%) patients
who underwent radiologic intervention or surgical treatment for
anastomotic leakage were included in Grade III–IV. A few
previous studies have demonstrated that major complications
such as anastomotic leakage influence both local recurrence and
decreased survival rate.33–35 Consistent with these previous
results, the results of the present study showed that the presence
of major complications (grade III–IV) (P¼ 0.005; HR¼ 3.674)
was an independent prognostic factor for local recurrence in the
multivariate analysis. The reason for the association between
anastomotic leakage and local recurrence is still unclear. How-
ever, several potential mechanisms responsible for local recur-
rence, such as deposition of viable tumor cells into the pelvis or
shedding into the bowel lumen, have been previously
reported.36,37 In addition, major complications may potentially
contribute to delayed adjuvant chemotherapy, further affecting
the patient survival. Based on these facts, the technical feasi-
bility and oncologic safety should be considered when deciding
on adopting robotic technology.
This case-matched study aimed to elucidate the potential
advantages of robotic surgery in patients with rectal cancer by
comparing totally robotic and L-TME. However, the results of
R-TME in the current study did not show any superior long-term
oncologic outcomes compared with L-TME. In terms of over-
coming the technical difficulty associated with narrow pelvis
and in terms of the potential functional benefits such as earlier
recovery of voiding function, the robotic technique is theoreti-
cally an attractive treatment option to both surgeons and
patients. However, based on our findings herein, major draw-
backs of R-TME include a significant longer operation time as
well as the lack of substantial superiority over L-TME. In
addition, although our study did not assess the cost efficiency
of robotic surgery, the higher cost of robotics versus laparo-
scopy should be considered when adopting robotic surgery in
patients with rectal cancer.
In conclusion, both L-TME and R-TME are feasible
approaches for the treatment of rectal cancer in terms of the
postoperative complications, and short- and long-term out-
comes. However, any true benefits of robotic surgery are
still questionable, and whether R-TME can be justified as a
standard procedure in rectal cancer patients needs to be
further clarified.
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